Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 589.77% and ...

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100 ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Lilly and Danish rival Novo Nordisk (NOVOb.CO ... with a base salary of $1 million and eligibility for an annual target bonus of $1 million.

Three months on, Eli Lilly has closed the books on its search for a new chief financial officer. And as with its previous CFO ...

BMO Capital maintained its Outperform rating on Eli Lilly shares (NYSE:LLY), with a price target of $1,101.00. The firm highlighted Eli Lilly's commitment to enhancing its manufacturing capabilities, ...

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...

Shortly after a positive data drop for Eli Lilly’s efsitora a | Lilly revealed that its weekly insulin candidate efsitora ...